Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Combining for CD8
May 2020
SHARING OPTIONS:

LOS ANGELES—ImaginAb Inc. and AstraZeneca have inked a multiyear, non-exclusive license agreement under which ImaginAb's CD8 ImmunoPET technology will be applied in AstraZeneca's North American and European clinical trials. Specific financial details were not released, but ImaginAb stands to receive license fees and other contingent payments under this agreement.
 
“We are very pleased that AstraZeneca is expanding our relationship. Under the new agreement, ImaginAb will provide AstraZeneca with clinical doses of ImaginAb’s CD8 ImmunoPET minibody, as well as technical support, to AstraZeneca clinical trials involving novel immunotherapies. ImaginAb’s CD8 ImmunoPET technology is the clinically most advanced CD8 PET tracer. It is a powerful diagnostic approach for measuring non-invasively the effect of immunotherapies, which we believe will ultimately be used to predict therapeutic efficacy,” said ImaginAb CEO Ian Wilson.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.